TECHWIRE 30
(CIX: WRAL30)  1,046.27  up arrow+4.52  (0.43 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NQ: Apple)  99.76  up arrow+2.09  (2.14 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NY: QUINTILES)  54.78  down arrow-0.52  (-0.94 %)  Updated: 06:40 PM EDT, Oct 20 2014
(OP: BASF SE)  87.47  down arrow-0.95  (-1.07 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NQ: BioCryst)  11.60  up arrow+0.02  (0.17 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NQ: BioDelivery)  16.74  up arrow+0.79  (4.95 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NQ: CEMP)  12.22  down arrow-0.03  (-0.24 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NQ: Cisco Systems)  22.93  down arrow-0.32  (-1.38 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NQ: Cree)  32.90  down arrow-0.23  (-0.69 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NQ: DARA)  0.86  down arrow-0.01  (-1.15 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NY: EMC CORPORATION)  26.95  down arrow-0.16  (-0.59 %)  Updated: 06:40 PM EDT, Oct 20 2014
(NQ: Extreme Networks)  3.16  up arrow+0.1  (3.1 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NQ: FB)  76.95  up arrow+1  (1.32 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NY: GLAXOSMITHKLINE)  43.61  down arrow-0.06  (-0.14 %)  Updated: 06:40 PM EDT, Oct 20 2014
(NQ: GOOG)  520.84  up arrow+9.67  (1.89 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NY: IBM)  169.10  down arrow-12.95  (-7.11 %)  Updated: 06:40 PM EDT, Oct 20 2014
(NY: LH)  98.94  up arrow+0.27  (0.27 %)  Updated: 06:40 PM EDT, Oct 20 2014
(OP: Lenovo Group)  28.53  up arrow+0.52  (1.84 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NY: MRK)  54.05  up arrow+0.03  (0.06 %)  Updated: 06:40 PM EDT, Oct 20 2014
(NQ: Microsoft Corp)  44.08  up arrow+0.45  (1.03 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NQ: NTAP)  38.54  down arrow-0.28  (-0.72 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NY: NOVARTIS AG)  87.90  up arrow+1.27  (1.47 %)  Updated: 06:40 PM EDT, Oct 20 2014
(OP: Novozymes A/S)  40.39  up arrow+0.45  (1.11 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NY: PFIZER)  27.93  up arrow+0.1  (0.36 %)  Updated: 06:40 PM EDT, Oct 20 2014
(NQ: Pozen)  8.08  down arrow-0.04  (-0.49 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NY: RED HAT)  56.34  up arrow+0.65  (1.17 %)  Updated: 06:40 PM EDT, Oct 20 2014
(NQ: BBRY)  10.30  up arrow+0.81  (8.54 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NQ: Salix)  141.99  up arrow+1.99  (1.42 %)  Updated: 08:10 PM EDT, Oct 20 2014
(NQ: SQI)  15.09  up arrow+0.05  (0.33 %)  Updated: 08:10 PM EDT, Oct 20 2014

Posts tagged “PRA International”

Updated September 9

Premium Lock PRA Health Sciences files for $375M stock offering

PRA Health Sciences, which was taken private in a $1.3 billion deal a year ago, is looking to return to the public markets through a $375 million IPO.

PRA Health Sciences PRA Health Sciences

November 14, 2013

Premium Lock PRA International to acquire 250-employee research organization

PRA Intrernational The Raleigh-based clinical research organization plans to acquire CRI Lifetree, a research organization with 250 employees. It is privately held and is based in New Jersey.

September 24, 2013

Premium Lock PRA completes merger with RPS, forms fourth largest CRO

PRA Intrernational The merger is the second major transaction for PRA this year, following its acquisition in June by private equity firm KKR. Read more about the company.

Updated September 12, 2013

Premium Lock PRA International proposes $375 private debt offering to finance M&A deals

PRA International's private equity owner KKR reportedly needs $950 million to finance its CRO acquisitions. Read more about the proposed offering.

PRA Intrernational PRA Intrernational

Updated July 31, 2013

Premium Lock Private equity firm KKR to merge PRA International with Pennsylvania CRO

PRA Intrernational The planned CRO merger comes a month after private equity firm KKR reached a deal to acquire PRA International. Read more about the plans.

Updated July 31, 2013

Premium Lock Private equity firm KKR to merge PRA International with Pennsylvania CRO

PRA Intrernational The planned merger comes a month after private equity firm KKR reached a deal to acquire PRA International. Read more about the plans.

Updated June 25, 2013

Premium Lock Raleigh health firm PRA sold to private equity firm in deal reportedly worth $1.3B

PRA International had been exploring a possible initial public stock offering. Instead, it is being sold to private equity firm KKR. For the moment, companies involved are being quiet about most details - including the acquisition price. But media reports had estimated a selling price of around $1.3 billion.

PRA CEO Colin Shannon discusses sale PRA CEO Colin Shannon discusses sale

June 5, 2013

Premium Lock Raleigh CRO PRA weighs private equity bids against IPO plans

PRA Intrernational Even as PRA International explores a possible initial public stock offering, the clinical trials firm is also reportedly the target of private equity bidders who could buy the company for up to $1.3 billion.

Updated May 17, 2013

Premium Lock Raleigh-based PRA International eyes public offering

Another life science services firm in the Triangle, PRA International, may follow in the footsteps of a bigger rival - Quintiles - by offering stock in order to raise capital. Just two years ago, PRA was at the center of takeover rumors in the range of $1 billion.

PRA's corporate timeline PRA's corporate timeline

Updated March 6, 2013

Premium Lock PRA acquires ClinStar; Raleigh CRO boosts global reach

PRA logo Raleigh contract research organization PRA International, aiming to boost its capabilities to run global clinical trials, has acquired the Eastern Europe-focused CRO ClinStar.

Updated June 5, 2012

Premium Lock Pharma survey a split verdict for Quintiles, other service firms

Medical science Quintiles is tops in a survey of pharmaceutical firms. However, the report also finds disastisfaction also finds that nearly half would prefer to pick trial doctors to run studies rather than clinical research organizations such as Quintiles.

April 27, 2012

Premium Lock Raleigh firm PRA lands clinical trial deal with Amgen

PRA Intrernational PRA has entered into a strategic partnership with Amgen to do work on a series of phase 3 studies to develop biosimilar drugs. Biosimilars are follow-on biologic drugs that are cheaper than very expensive biologic drugs.

Updated December 26, 2011

Premium Lock What's on shopping list for CROs in the new year?

Biotech & Life Science Partners, M&A possibilities, sites in Asia, private equity investments and more consulting expertise are appealing items on the want lists for contract research organizations.

October 4, 2011

Premium Lock PRA International may be nearing sale topping $1B

PRA The Raleigh-based life science services firm is in the process of an "auction," according to The Wall Street Journal. If so, PRA would be the second regional contract research organization sold this fall. PPD is being sold for $3.9 billion.

July 18, 2011

Premium Lock PPD to explore 'unlocking value;' rumors send stock surging 10.3%

Fred Eshelman   In a statement issued after a report about the company possibly being sold, Pharmaceutical Product Development says it management will "review" PPD's strategic plan and capital structure.

Updated July 18, 2011

Premium Lock PPD shares soar 17% on sale report; PRA on block, too?

PPD PRA International, which is based in Raleigh, and Pharmaceutical Product Development, which operates out of Wilmington, are looking for buyers, according to The Wall Street Journal.

June 15, 2011

Premium Lock PRA expands clinical research services in Sweden

PRA The Raleigh-based contract research organization operates some 40 offices worldwide.

Updated December 14, 2009

Premium Lock PRA International promotes its chief operating officer to top job

Colin Shannon Colin Shannon, a longtime executive at Pharmaceutical Product Development, will replace Terry Bieker as chief executive of PRA. Bieker, who is retiring, will remain a member of the contract research organization's board.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll